Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node Positive HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339281
What this trial is testing

Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Li Huiping 68
Not applicableLooking for participantsNCT07546695
What this trial is testing

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Who this might be right for
Breast Cancer
University Hospital, Basel, Switzerland 600
Early research (Phase 1)Not Yet RecruitingNCT07601620
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 258
Not applicableLooking for participantsNCT05314114
What this trial is testing

Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT

Who this might be right for
Breast Cancer Female
Peking University 136
Testing effectiveness (Phase 2)Study completedNCT01421472
What this trial is testing

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Who this might be right for
ER Positive, Her2 Negative Breast Cancer PatientsTriple Negative Breast Cancer Patients
Merrimack Pharmaceuticals 196
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Very early researchActive Not RecruitingNCT05333874
What this trial is testing

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Who this might be right for
Breast Cancer, Early-Onset
Rutgers, The State University of New Jersey 34
Testing effectiveness (Phase 2)Looking for participantsNCT07285382
What this trial is testing

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo 120
Not applicableStudy completedNCT00911716
What this trial is testing

TC Avastin. ICORG 08-10, V6

Who this might be right for
Breast Cancer
Cancer Trials Ireland 106
Testing effectiveness (Phase 2)Looking for participantsNCT07407920
What this trial is testing

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 120
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Not applicableStudy completedNCT05709158
What this trial is testing

Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Who this might be right for
Breast Cancer
Pfizer 4,184
Large-scale testing (Phase 3)Active Not RecruitingNCT00070564
What this trial is testing

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 3,294
Early research (Phase 1)Study completedNCT01921335
What this trial is testing

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Who this might be right for
Brain Metastases From HER2 and Breast CancerAdvanced HER2-positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116
Testing effectiveness (Phase 2)Ended earlyNCT04142060
What this trial is testing

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT05467891
What this trial is testing

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Locoregional RecurrenceHormone Receptor-positive Breast CancerHER2-negative Breast Cancer
Oana Danciu 200
Next Page